Tuesday, December 5, 2023
WebMD Global requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.
Partner
California Retina Consultants
Director
California Retina Research Foundation
Santa Barbara, California, United States
Clinical Assistant Professor
University of Illinois Chicago
Director of Clinical Research
University Retina and Macula Associates
Chicago, Illinois, United States
Professor of Ophthalmology
Director
Department of Ophthalmology
University of Ulm
Ulm, Germany
This activity has been peer reviewed and the reviewer has no relevant financial relationships.
processing....
Posted: 03/11/2022
This activity is intended for an international audience of non-US ophthalmologists, other eye care professionals, and all physicians who care for patients with neovascular age-related macular degeneration (nAMD).
Upon completion of this activity, participants will be able to:
The goal of this activity is for learners to be better able to select patients with nAMD who might benefit from anti-VEGF implant therapy, based on clinical data and best practices.
Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.
